




Certificate of Mailing		
Date of Deposit: July 12, 2006	Label Number: EV 768765377US	
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.		
Elvis De La Cruz		
Printed name of person mailing correspondence	Signature of person mailing correspondence	
Substitute Form PTO 1390 U.S. Department of Commerce Patent and Trademark Office TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. § 371		Attorney Docket Number: 50120/008001 U.S. Application Number: 107585772
INTERNATIONAL APPLICATION NUMBER	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/CA05/00040	January 12, 2005	January 12, 2004
TITLE OF INVENTION:	ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE REDUCATASE R2 AND USES THEREOF IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCER	
APPLICANTS FOR DO/EO/US:	Aiping H. YOUNG, Jim A. WRIGHT, and Yoon LEE	
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1.	<input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371.	
2.	<input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371.	
3.	<input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. § 371(f)).	
4.	<input checked="" type="checkbox"/> The U.S. has been elected.	
5.	<input checked="" type="checkbox"/> A copy of the International Application (35 U.S.C. § 371(c)(2)). <input checked="" type="checkbox"/> a. is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. has been transmitted by the International Bureau. <input type="checkbox"/> c. Is not required, as the application was filed with the United States Receiving Office (RO/US).	
6.	<input type="checkbox"/> An English language translation of the International Application into English (35 U.S.C. § 371(c)(2)). <input type="checkbox"/> a. is transmitted herewith. <input type="checkbox"/> b. has been previously submitted under 35 U.S.C. 154(d)(4).	
7.	<input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)). <input type="checkbox"/> a. are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> b. have been transmitted by the International Bureau. <input type="checkbox"/> c. have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> d. have not been made and will not be made.	
8.	<input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)).	
9.	<input checked="" type="checkbox"/> An oath or declaration of the inventors (35 U.S.C. § 371(c)(4)). (unsigned)	
10.	<input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371 (c)(5)).	
11.	<input checked="" type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98.	
12.	<input type="checkbox"/> An assignment for recording. A separate cover sheet in compliance with 37 C.F.R. §§ 3.28 and 3.31 is included.	
13.	<input checked="" type="checkbox"/> A preliminary amendment.	
14.	<input type="checkbox"/> A substitute specification.	
15.	<input type="checkbox"/> A power of attorney and/or change of address letter.	
16.	<input type="checkbox"/> Request for Deferred Examination.	
17.	<input checked="" type="checkbox"/> Application Data Sheet.	
18.	<input checked="" type="checkbox"/> Other items or information: Statement Under 37 C.F.R. § 1.821 (2 pgs.); Sequence Listing (26 pgs.); Sequence Diskette; IB308 (1 page); PCT/RO/101 (4 pages).	

36-393472

IAP20 Rec'd PCT/PTO 12 JUL 2006

<input checked="" type="checkbox"/> The following fees are submitted:			
Basic National Stage Fee: \$300			
National Stage Search Fee Search fee (37 C.F.R. § 1.445(a)(2)) has been paid on the international application to the USPTO as an International Search Authority: \$100 International Search Report prepared and provided to the Office: \$400 All other situations: \$500			
National Stage Examination Fee If International preliminary examination report prepared by USPTO and all claims satisfied provisions of PCT Articles 33(1)-(4): \$100 All other situations: \$200			
Surcharge of \$130 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(e)). \$			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	38 - 20 =	18	x \$50 \$900
Independent claims	4 - 3 =	1	x \$200 \$200
Multiple dependent claims (if applicable)			+ \$360 \$
Application Size Fee: Additional fee for specification and drawings in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.			
TOTAL SHEETS	EXTRA SHEETS	Number of each additional 50 sheets or fraction thereof (round up to a whole number)	RATE
-100=	/50=		X\$250 \$250.00
TOTAL OF ABOVE CALCULATIONS = \$2,250.00			
Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status under 37 C.F.R. § 1.27			
SUBTOTAL = \$			
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(f)). +			
TOTAL NATIONAL FEE = \$ 2,250.00			
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§ 3.28, 3.31). \$40.00 per property. +			
TOTAL FEES ENCLOSED = \$ 2,250.00			
		Amount to be refunded	\$
		charged	\$
<input checked="" type="checkbox"/> a. A check in the amount of \$2,250.00 to cover the above fees is enclosed. <input type="checkbox"/> b. Please charge my Deposit Account No. 03-2095 in the amount of \$ [*] to cover the above fees. <input type="checkbox"/> c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 03-2095.			
NOTE: Where an appropriate time limit under 37 C.F.R. §§ 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. § 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO:		 Signature Kristina Bieker-Brady, Ph.D. Reg. No. 39,109	
Kristina Bieker-Brady, Ph.D. Clark & Elbing LLP 101 Federal Street Boston, MA 02110-2214		Telephone: 617-428-0200 Facsimile: 617-428-7045 Customer No.: 21559	
		 Karen L. Elbing Reg. No. 35,238 FOR	

336535172

Express Mail Service 12 JUL 2006

Certificate of Mailing

Date of Deposit: July 12, 2006


Label Number: EV768765377US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elvis De La Cruz

Printed name of person mailing correspondence

Signature of person mailing correspondence



APPLICATION
FOR
UNITED STATES LETTERS PATENT

APPLICANTS: Aiping H. YOUNG, Jim A. WRIGHT, and Yoon LEE

TITLE: ANTISENSE OLIGONUCLEOTIDES DIRECTED TO
RIBONUCLEOTIDE REDUCATASE R2 AND USES
THEREOF IN COMBINATION THERAPIES FOR THE
TREATMENT OF CANCER